Intercept Pharmaceuticals (ICPT)

[crepenutella]

Chinese company interested in NASH treatment

An imminent partnership could be signed with a chinese biopharma ...

Genfit , a french company working on the NASH and is working in a better treatment with a larger application.

The DSMB approved the continuation of the phase 2b study in NASH last october 2013.

The members of the DSMB unanimously concluded that, after
more than 6 months of treatment at the dose of 80 mg/day,
GFT505 shows no safety issue that compromises the
continuation of the Phase IIb study.

Intercept failed recently in nash ... and it's valued at $ 1 billion ... 5 times less than Genfit, valued at $ 224 million.

More information ( english version )
http://genfit.com/en/home/index.html

Stock information : 8,13 euros ( today )
Portzamparc's objective : 15,40 euros